.Pharmacolibrary.Drugs.ATC.J.J05AJ02 .Pharmacolibrary.Drugs.ATC.J.J05AJ02| name: | Elvitegravir |
| ATC code: | J05AJ02 | route: | oral |
| n-compartments | 2 |
Elvitegravir is an antiretroviral medication used as an integrase inhibitor in the treatment of HIV-1 infection. It is approved for use as part of combination antiretroviral therapy in adults and adolescents.
Population pharmacokinetic parameters reported in healthy adult subjects; oral administration; studies primarily in healthy volunteers.
Yamada, H, et al., & Irie, S (2018). Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects. Clinical pharmacology in drug development 7(2) 132–142. DOI:10.1002/cpdd.365 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28581645
Ogbuagu, O (2016). Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert review of anti-infective therapy 14(12) 1113–1126. DOI:10.1080/14787210.2016.1255551 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27797606